Loading clinical trials...
Loading clinical trials...
A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Conditions
Interventions
NOV03
Locations
28
United States
Bausch Site 124
Birmingham, Alabama, United States
Bausch Site 125
Scottsdale, Arizona, United States
Bausch Site 110
Glendale, California, United States
Bausch Site 121
Long Beach, California, United States
Bausch Site 102
Mission Hills, California, United States
Bausch Site 101
Newport Beach, California, United States
Start Date
September 24, 2020
Primary Completion Date
January 5, 2022
Completion Date
January 5, 2022
Last Updated
March 4, 2024
NCT07463950
NCT07396441
NCT06984549
NCT06841471
NCT07268599
NCT07503886
Lead Sponsor
Bausch & Lomb Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions